Table 2.
Prevalence of histologic results among patients with lesions classified with different PI-RADS scores
| PCa | csPCa | ciPCa | Negative | p value* | |
|---|---|---|---|---|---|
| 3, n (prevalence, %) | 12 (15.0) | 2 (2.5) | 10 (12.5) | 68 (85.0) | < 0.001 |
| 3up, n (prevalence, %) | 17 (24.6) | 10 (14.5) | 7 (10.1) | 52 (75.4) | < 0.001 |
| 4, n (prevalence, %) | 104 (77.0) | 72 (53.3) | 32 (23.7) | 31 (23.0) | < 0.001 |
| 4 + 3up, n (prevalence, %) | 121 (78.4) | 82 (40.2) | 39 (19.1) | 83 (40.7) | < 0.001 |
| 5, n (prevalence, %) | 60 (88.2) | 50 (73.5) | 10 (14.7) | 8 (11.8) | < 0.001 |
* p value < 0.05 was considered for statistical significance (bold values within the table), calculated comparing three groups: negative patients, patients with ciPCa, and patients with csPCa
PI-RADS, Prostate Imaging—Reporting and Data System; PCa, prostate cancer; csPCa, clinically significant prostate cancer; ciPCa, clinically insignificant prostate cancer